Sangamo Therapeutics, Inc. reported impairment results for the fourth quarter ended December 31, 2023. For the quarter, the company reported Impairment of long-lived assets of $0.3 million.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.5024 USD | -6.95% | -7.61% | -7.53% |
03-22 | Sangamo Therapeutics Prices $24 Million Registered Direct Offering | MT |
03-14 | Sangamo Therapeutics Pushes Neurology Programs Toward Clinical Development, Wedbush Says | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-7.53% | 104M | |
+2.93% | 108B | |
+8.82% | 105B | |
+0.58% | 23.46B | |
-14.60% | 21.72B | |
-7.05% | 18.64B | |
-38.55% | 17.45B | |
-8.83% | 17.19B | |
+5.51% | 13.99B | |
+37.49% | 12.53B |
- Stock Market
- Equities
- SGMO Stock
- News Sangamo Therapeutics, Inc.
- Sangamo Therapeutics, Inc. Reports Impairment Results for the Fourth Quarter Ended December 31, 2023